Abciximab Suppresses the Rise in Levels of Circulating Inflammatory Markers After Percutaneous Coronary Revascularization
Key result
Periprocedural abciximab blunts the post-angioplasty rise in CRP by ~32% versus placebo.
- 32% less increase
- P=0.025
- n=160
Why the study?
Does abciximab reduce the rise in circulating inflammatory markers in patients undergoing percutaneous coronary revascularization?
Population
160 patients undergoing percutaneous coronary revascularization (angioplasty)
Comparison
Abciximab bolus plus a 12-hour infusion during… vs Placebo bolus plus a 12-hour infusion
Design
RCT, randomized, placebo-controlled
Follow-up
4 weeks
Authors
Discussion
Loading...
Member takes
Implication
Hypothesis-generating for anti-inflammatory effects of abciximab; leaves open clinical outcome benefits and requires prospective validation.
Study Design
Type
RCT (n=160)
Blinding
Placebo-controlled
Randomization
Randomized
Structured PICO
Does abciximab reduce the rise in circulating inflammatory markers in patients undergoing percutaneous coronary revascularization?
P
Population
160 patients undergoing angioplasty, randomized to abciximab or placebo and followed for 4 weeks.
I
Intervention
Abciximab bolus plus a 12-hour infusion during angioplasty
C
Comparator
Placebo bolus plus a 12-hour infusion
O
Outcome
Levels of inflammatory markers (C-reactive protein, interleukin-6, and tumor necrosis factor-alpha) at 24 to 48 hours and 4 weeks after study drug administrationsurrogate
Main Result
Effect estimate: 32% less increase
p-value: p=0.025
Periprocedural abciximab significantly blunts the acute rise in systemic inflammatory markers (CRP and IL-6) following percutaneous coronary revascularization.
Cite This Study
Lincoff et al. (2001) conducted an RCT in Percutaneous coronary revascularization (angioplasty) (n=160). Abciximab vs. Placebo was evaluated on Increase in C-reactive protein between baseline and 24 to 48 hours (32% less increase, p=0.025). Periprocedural abciximab during angioplasty significantly reduced the rise in C-reactive protein (by 32%, P=0.025) and interleukin-6 (by 76%, P<0.001) at 24 to 48 hours compared to placebo.